Stereotactic radiotherapy alone or followed by niraparib for oligometastases or oligoprogression in ovarian cancer following PARP inhibitor therapy.
Who can take part
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
You may be able to take part in this trial if you:
- are aged 18 years or older
- have epithelial ovarian, fallopian tube or primary peritoneal cancer
- have disease progression, that can be seen on scan while on or following any parp inhibitor therapy (Olaparib, Rucaparib or Niraparib).
- had a parp inhibitor as the last type of treatment you received
- had at least 6 months of a Parp inhibitor therapy as either part of first line therapy or treatment for recurrence
- have 3 sites or less of cancer that are getting worse
- have disease big enough to be treated by stereotactic radiotherapy
- are in good physical health
- have a tissue sample of the cancer that the team can use. If this isn’t available, you must be willing to have a fresh biopsy taken
- are willing to take reliable contraception if there is a chance that you can become pregnant
This is not an exhaustive list. If you're interested in participating in a clinical trial, you should speak to your doctor about what other criteria might apply.
About the trial
The Soprano trial is looking at whether a type of radiotherapy, called stereotactic radiotherapy, used on its own or with a type of PARP inhibitor called Niraparib can delay the time before the ovarian cancer starts to grow again and require another type of treatment, like chemotherapy. The study will also look at the side effects of the treatments and their effects on quality of life.
To be able to take part in this trial you will need to have cancer deposits that have got bigger or spread to a small number of places (oligoprogression). The cancer must only be seen on scan in 1 – 3 places in the body (oligometasteses).
The treatments involved in this study are:
- Stereotactic radiotherapy – this is a particular way of giving radiotherapy (high dose energy X rays that kill cancer cells). The radiotherapy is given from lots of different angles around the body that meet where the cancer is. This allows the highest dose of radiotherapy to be given directly to the cancer and reduces the dose to the surrounding tissue and therefore the associated side effects.
- Niraparib (a tablet taken by mouth) – this is a type of PARP inhibitor. PARP inhibitors are a type of targeted therapy which can be used to stop cancer cells repairing DNA damage within themselves, so the cancer cells die.
If you take part in the trial, you will choose one of two treatment options:
- Stereotactic radiotherapy followed by niraparib
- Stereotactic radiotherapy alone
All participants will be followed up by the research team.
This information was last reviewed on 12/06/2026. Please note that the status of clinical trials can change at short notice. You should always check with your clinical team which trials may be suitable for your situation.
